Akkaraju Srinivas's Insider Trades & SAST Disclosures
Akkaraju Srinivas's most recent trade in Alumis Inc. was a trade of 159,920 Common Stock done at an average price of $4.6 . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Akkaraju Srinivas.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alumis Inc. | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 4.55 per share. | 02 May 2025 | 159,920 | 3,426,418 | - | 4.6 | 727,636 | Common Stock |
| Alumis Inc. | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 02 May 2025 | 138,368 | 3,564,786 | - | 4.6 | 633,725 | Common Stock |
| Alumis Inc. | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 5.27 per share. | 02 May 2025 | 22,002 | 3,586,788 | - | 5.3 | 115,951 | Common Stock |
| Kalaris Therapeutics Inc. | Srinivas Akkaraju | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 13.50 per share. | 13 Mar 2025 | 600,000 | 5,674,916 | - | 13.5 | 8,100,000 | Common Stock |
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 32,900 | 32,900 | - | - | Stock Option | |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 07 Oct 2024 | 510,000 | 6,278,609 (21%) | 1% | 27.5 | 14,025,000 | Common Stock |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 07 Oct 2024 | 510,000 | 5,768,609 (19%) | 1% | 30 | 15,300,000 | Common Stock |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 07 Oct 2024 | 155,713 | 5,612,896 (18%) | 0% | 32.5 | 5,060,673 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,667 | 2,667 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,667 | 9,333 (0%) | 0% | - | Common Stock | |
| Alumis Inc. | Srinivas Akkaraju | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 1,703,998 | 0 | - | - | Class A Common Stock | |
| Alumis Inc. | Srinivas Akkaraju | Director | 01 Jul 2024 | 1,703,998 | 1,703,998 | - | - | Class A Common Stock | ||
| Alumis Inc. | Srinivas Akkaraju | Director | 01 Jul 2024 | 1,703,998 | 0 | - | - | Series C Preferred Stock | ||
| Alumis Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,703,998 | 1,703,998 | - | - | Common Stock | |
| Alumis Inc. | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 01 Jul 2024 | 1,562,500 | 3,266,498 | - | 16 | 25,000,000 | Common Stock |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 13,500 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 0 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 6,666 (0%) | 0% | - | Common Stock | |
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 22,000 | 22,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Akkaraju Srinivas | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 13.50 per share. | 12 Feb 2024 | 555,555 | 5,074,916 | - | 13.5 | 7,499,993 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 21 Dec 2023 | 904,977 | 1,786,427 (4%) | 2% | 4.4 | 3,999,998 | Common Stock |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 12,547 | 12,547 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 8,111 | 45,998 (0%) | 0% | 0 | Common Stock | |
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | 14 Feb 2023 | 3,581,861 | 3,581,861 | - | - | Common Stock | ||
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | 14 Feb 2023 | 2,135,504 | 0 | - | - | Series A Preferred Stock | ||
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | 14 Feb 2023 | 1,446,357 | 0 | - | - | Series B Preferred Stock | ||
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 14 Feb 2023 | 937,500 | 4,519,361 | - | 16 | 15,000,000 | Common Stock |
| Mineralys Therapeutics Inc | Srinivas Akkaraju | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 44,000 | 44,000 | - | - | Stock Option | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 691,489 | 691,489 | - | - | Warrants (right to buy) | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 691,489 | 881,450 (2%) | 1% | - | Common Stock | |
| Scholar Rock Holding Corp | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 56,000 | 56,000 | - | - | Stock Option (Right to Buy) | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 12,790 | 12,790 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 7,737 | 37,887 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 12,089 | 12,089 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,029 | 30,150 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 21.29 per share. | 10 Mar 2021 | 147,000 | 640,688 (1%) | 0% | 21.3 | 3,129,630 | Common Stock |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 20.83 per share. | 10 Mar 2021 | 73,441 | 477,129 (1%) | 0% | 20.8 | 1,529,776 | Common Stock |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 21.55 per share. | 10 Mar 2021 | 16,559 | 493,688 (1%) | 0% | 21.5 | 356,846 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 13.10 per share. | 17 Aug 2020 | 158,583 | 1,274,616 (2%) | 0% | 13.1 | 2,076,724 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 17 Aug 2020 | 744 | 1,433,199 (3%) | 0% | 13 | 9,672 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.01 per share. | 01 Jul 2020 | 4,627 | 1,433,943 (3%) | 0% | 11.0 | 50,966 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.15 per share. | 23 Jun 2020 | 54,972 | 1,438,570 (3%) | 0% | 11.1 | 612,850 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.11 per share. | 23 Jun 2020 | 50,953 | 1,542,317 (3%) | 0% | 11.1 | 565,930 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.07 per share. | 23 Jun 2020 | 48,775 | 1,493,542 (3%) | 0% | 11.1 | 539,788 | Common Stock |
| Syros Pharmaceuticals Inc. | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,966 | 2,966 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 1,595 | 23,121 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges